ModernGraham Valuation

Company Name:

Company Ticker ABBV Date of Analysis AbbVie Inc



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

3/3/2019

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$118,154,226,149	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	0.98	Fail
3.	Earnings Stability	Positive EPS for 10 years prior		Fail
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	363.28%	Pass
6.	Moderate PEmg Ratio	PEmg < 20	15.46	Pass
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	-14.24	Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.				

1.	. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.98	Fail
2.	. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-119.05	Fail
3.	. Earnings Stability	Positive EPS for 5 years prior		Pass
4.	Dividend Record	Currently Pays Dividend		Pass
5.	. Earnings Growth	EPSmg greater than 5 years ago		Pass
		Score		

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

	EPSmg		\$5.18
	MG Growth Estimate		15.00%
	MG Value		\$199.51
	MG Value based on 3% Growth		\$75.14
	MG Value based on 0% Growth		\$44.05
	Market Implied Growth Rate		3.48%
MG Opinion			
	Current Price		\$80.10
	% of Intrinsic Value		40.15%
	Opinion	Undervalued	
	MG Grade	C	


Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$33.88
Graham Number	\$0.00
PEmg	15.46
Current Ratio	0.98
PB Ratio	-14.24
Current Dividend	\$3.59
Dividend Yield	4.48%
Number of Consecutive Years of Dividend	
Growth	6

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate		Next Fiscal Year Estimate	\$5.18
Dec2018	\$3.66	Dec2018	\$3.32
Dec2017	\$3.30	Dec2017	\$3.01
Dec2016	\$3.63	Dec2016	\$2.83
Dec2015	\$3.13	Dec2015	\$2.30
Dec2014	\$1.10	Dec2014	\$1.72
Dec2013	\$2.56	Dec2013	\$1.75
Dec2012	\$3.35	Dec2012	\$1.12
Dec2011	\$0.00	Dec2011	\$0.00
Dec2010	\$0.00	Dec2010	\$0.00
Dec2009	\$0.00	Dec2009	\$0.00
Dec2008	\$0.00	Dec2008	\$0.00
Dec2007	\$0.00	Dec2007	\$0.00
Dec2006	\$0.00	Dec2006	\$0.00
Dec2005	\$0.00	Dec2005	\$0.00
Dec2004	\$0.00	Dec2004	\$0.00
Dec2003	\$0.00	Dec2003	\$0.00
Dec2002	\$0.00	Balance Sheet Information	12/1/2018
Dec2001	\$0.00	Total Current Assets	\$16,945,000,000
Dec2000	\$0.00	Total Current Liabilities	\$17,239,000,000
Dec1999	\$0.00	Long-Term Debt	\$35,002,000,000
		Total Assets	\$59,352,000,000
		Intangible Assets	\$36,896,000,000
		Total Liabilities	\$67,798,000,000
		Shares Outstanding (Diluted Average)	1,501,000,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company	<u>10 Best Dividend Paying Stocks for the Enterprising Investor – May 2018</u> <u>AbbVie Inc Valuation – April 2018 \$ABBV</u> 10 Stocks for Using A Benjamin Graham Value Investing Strategy – January 2017
	9 Best Stocks For Value Investors This Week – 7/23/16
	AbbVie Inc Valuation – July 2016 \$ABBV
Other ModernGraham posts about related companies	Allergan PLC Valuation – February 2019 \$AGN Incyte Corp Valuation – February 2019 \$INCY Regeneron Pharmaceuticals Inc Valuation – February 2019 \$REGN Alexion Pharmaceuticals Inc Valuation – February 2019 \$ALXN Vertex Pharmaceuticals Inc Valuation – February 2019 \$VRTX Perrigo Company Valuation – February 2019 \$PRGO Eli Lilly and Co Valuation – January 2019 \$LLY

Eli Lilly and Co Valuation – January 2019 \$LLY Zoetis Inc Valuation – January 2019 \$ZTS Gilead Sciences Inc Valuation – January 2019 \$GILD Pfizer Inc Valuation – November 2018 \$PFE